TY - JOUR A2 - Xiang, Guang-Da AU - Wu, Haishan AU - Deng, Lu AU - Zhao, Lipin AU - Zhao, Jingping AU - Li, Lehua AU - Chen, Jindong PY - 2013 DA - 2013/04/17 TI - Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia SP - 167138 VL - 2013 AB - Schizophrenia is one of the most common global mental diseases, with prevalence of 1%. Patients with schizophrenia are predisposed to diabetes, coronary heart disease, hypertension, and osteoporosis, than the normal. In comparison with the metabolic syndrome, for instance, there are little reports about osteoporosis which occurs secondary to antipsychotic-induced hyperprolactinaemia. There are extensive recent works of literature indicating that osteoporosis is associated with schizophrenia particularly in patients under psychotropic medication therapy. As osteoporotic fractures cause significantly increased morbidity and mortality, it is quite necessary to raise the awareness and understanding of the impact of antipsychotic-induced hyperprolactinaemia on physical health in schizophrenia. In this paper, we will review the relationship between schizophrenia, antipsychotic medication, hyperprolactinaemia, and osteoporosis. SN - 1687-8337 UR - https://doi.org/10.1155/2013/167138 DO - 10.1155/2013/167138 JF - International Journal of Endocrinology PB - Hindawi Publishing Corporation KW - ER -